Shannon L. Devers - 07 Jan 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
EVP, Chief Human Resources Ofc
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Shannon L. Devers
Issuer symbol
IONS
Transactions as of
07 Jan 2026
Net transactions value
-$1,495,162
Form type
4
Filing time
09 Jan 2026, 17:08:28 UTC
Previous filing
06 Jan 2026
Next filing
20 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Devers Shannon L. EVP, Chief Human Resources Ofc 2855 GAZELLE COURT, CARLSBAD By: Patrick R. O'Neil, attorney-in-fact For: Shannon L. Devers 08 Jan 2026 0002037721

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $1,450,445 +25,545 +146% $56.78 43,039 07 Jan 2026 Direct
transaction IONS Common Stock Sale $2,180,521 -25,545 -59% $85.36 17,494 07 Jan 2026 Direct F1, F2
transaction IONS Common Stock Options Exercise $68,493 +2,101 +12% $32.60 19,595 07 Jan 2026 Direct
transaction IONS Common Stock Sale $179,341 -2,101 -11% $85.36 17,494 07 Jan 2026 Direct F1, F2
transaction IONS Common Stock Options Exercise $112,796 +3,460 +20% $32.60 20,954 07 Jan 2026 Direct
transaction IONS Common Stock Sale $292,785 -3,460 -17% $84.62 17,494 07 Jan 2026 Direct F1, F3
transaction IONS Common Stock Options Exercise $143,894 +3,829 +22% $37.58 21,323 07 Jan 2026 Direct
transaction IONS Common Stock Sale $324,010 -3,829 -18% $84.62 17,494 07 Jan 2026 Direct F1, F3
transaction IONS Common Stock Options Exercise $489,788 +9,264 +53% $52.87 26,758 07 Jan 2026 Direct
transaction IONS Common Stock Sale $783,920 -9,264 -35% $84.62 17,494 07 Jan 2026 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -2,101 -16% $0.000000 11,339 07 Jan 2026 Common Stock 2,101 $32.60 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -3,460 -31% $0.000000 7,879 07 Jan 2026 Common Stock 3,460 $32.60 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -3,829 -29% $0.000000 9,254 07 Jan 2026 Common Stock 3,829 $37.58 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -9,264 -50% $0.000000 9,262 07 Jan 2026 Common Stock 9,264 $52.87 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -25,545 -90% $0.000000 2,971 07 Jan 2026 Common Stock 25,545 $56.78 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.10 to $85.64 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.08 to $85.08 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.